AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23212429 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with LBP severity and back-specific disability
Number of subjects: 202
Study 23212429 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with number of key osteopathic lesions
Number of subjects: 202
Study 20113921 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Behavioral Intervention (MBI) plus standard care
Number of subjects: 376
Study 20113921 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC) alone
Number of subjects: 376
Study 18042501 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease inhibitor (PI)
Number of subjects: 1360
Study 18042501 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-nucleoside reverse transcriptase inhibitor (NNRTI)
Number of subjects: 1360
Study 18042501 — intervention group
Group type: EXPERIMENTAL
Intervention: PI+NNRTI
Number of subjects: 1360
Study 18042501 — intervention group
Group type: COMPARATOR
Intervention: No virologic failure (control group)
Number of subjects: 1360
Study 16125661 — intervention group
Group type: EXPERIMENTAL
Intervention: 55 IU ovine hyaluronidase
Number of subjects: 1125
Study 16125661 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 IU ovine hyaluronidase
Number of subjects: 1125
Study 16125661 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 1125
Study 12141723 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol
Number of subjects: 34
Study 12141723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 11206234 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray (two sprays per nostril twice daily, 1.1 mg/day)
Number of subjects: 0
Study 11206234 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 0
Study 9641928 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide (Drogenil)
Number of subjects: 49
Study 9641928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 9641928 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide (Drogenil) with 6 week exclusions
Number of subjects: 49
Study 9641928 — intervention group
Group type: COMPARATOR
Intervention: Placebo with 6 week exclusions
Number of subjects: 49
Study 7978687 — intervention group
Group type: EXPERIMENTAL
Intervention: Technetium-99m (Tc) pyrophosphate scanning
Number of subjects: 15
Study 7978687 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Tc scan)
Number of subjects: 15
Study 2645030 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 per cent acyclovir ointment
Number of subjects: 80
Study 2645030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 409597 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% HEDP containing toothpaste
Number of subjects: 50
Study 30677038 — intervention group
Group type: EXPERIMENTAL
Intervention: Seropositivity to cysticercal antigens
Number of subjects: 3696
Study 29187313 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry Needling (DN) of the lumbar multifidus
Number of subjects: 47
Study 29187313 — intervention group
Group type: COMPARATOR
Intervention: Sham-Dry Needling (sham-DN)
Number of subjects: 47
Study 25535358 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading an LE‐eBook
Number of subjects: 1508
Study 25535358 — intervention group
Group type: COMPARATOR
Intervention: Reading a printed book
Number of subjects: 1508
Study 23819410 — intervention group
Group type: EXPERIMENTAL
Intervention: Traction of the cervical spine following collar zone massage with soft cervical collar
Number of subjects: 65
Study 23819410 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined physiotherapeutic treatment including collar zone massage, orthotraction therapy, and soft cervical collar
Number of subjects: 65
Study 21683020 — intervention group
Group type: EXPERIMENTAL
Intervention: Education DVD
Number of subjects: 509
Study 21683020 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 509
Study 19538331 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous platelet-rich plasma (PRP)
Number of subjects: 40
Study 19538331 — intervention group
Group type: COMPARATOR
Intervention: Open flap debridement (OFD)
Number of subjects: 40
Study 17144492 — intervention group
Group type: EXPERIMENTAL
Intervention: Human thrombin insufflated locally on the right side
Number of subjects: 80
Study 17144492 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline insufflated on the left side
Number of subjects: 80
Study 15574092 — intervention group
Group type: EXPERIMENTAL
Intervention: Squat Whole Body Vibration (SWBV)
Number of subjects: 14
Study 15574092 — intervention group
Group type: COMPARATOR
Intervention: Conventional Squats (S)
Number of subjects: 14
Study 15574092 — intervention group
Group type: COMPARATOR
Intervention: Both groups (SWBV and S)
Number of subjects: 14
Study 11413406 — intervention group
Group type: EXPERIMENTAL
Intervention: Chen Medium (CM)
Number of subjects: 20
Study 11413406 — intervention group
Group type: COMPARATOR
Intervention: Optisol GS
Number of subjects: 20
Study 9117021 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrogen dioxide (NO2) exposure (490 micrograms/m3)
Number of subjects: 18
Study 9117021 — intervention group
Group type: COMPARATOR
Intervention: Purified air exposure
Number of subjects: 18
Study 8345288 — intervention group
Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate (LE) 0.5% suspension, 1 drop 4 times daily for 42 days
Number of subjects: 0
Study 8345288 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone acetate (PA) 1.0%, 1 drop 4 times daily for 42 days
Number of subjects: 0
Study 3731678 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg PPA (sustained-release preparation)
Number of subjects: 18
Study 3731678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 30724693 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious Illness Conversation Guide training for clinicians
Number of subjects: 25
Study 29861230 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrument-assisted soft tissue mobilization (IASTM) treatments (six treatments over three weeks)
Number of subjects: 29
Study 29861230 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 29
Study 26681713 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg once daily
Number of subjects: 279
Study 26681713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279
Study 25284194 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 μg of sodium selenite once daily for 365 consecutive days
Number of subjects: 130
Study 25284194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 21862454 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-GDP PDF (Balance®; Fresenius Medical Care)
Number of subjects: 152
Study 21862454 — intervention group
Group type: COMPARATOR
Intervention: Conventional PDF (Stay safe®; Fresenius Medical Care)
Number of subjects: 152
Study 20814325 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate transdermal system (MTS)
Number of subjects: 64
Study 20814325 — intervention group
Group type: COMPARATOR
Intervention: Osmotic-release oral system methylphenidate (OROS MPH)
Number of subjects: 64
Study 20814325 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate transdermal system (MTS) with dose escalation to 30 mg per 9 hours
Number of subjects: 64
Study 20814325 — intervention group
Group type: COMPARATOR
Intervention: Osmotic-release oral system methylphenidate (OROS MPH) with dose escalation to 54 mg
Number of subjects: 64
Study 20814325 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate transdermal system (MTS) and OROS MPH
Number of subjects: 64
Study 17650795 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuzheng Jiedu Granule (FJG) plus Western medicine
Number of subjects: 60
Study 17650795 — intervention group
Group type: COMPARATOR
Intervention: Western medicine alone
Number of subjects: 60
Study 16131620 — intervention group
Group type: EXPERIMENTAL
Intervention: Situational constraints reflecting plausible motives for essay writing behavior
Number of subjects: 0
Study 16131620 — intervention group
Group type: COMPARATOR
Intervention: Situational constraints (perceptually increasing salience)
Number of subjects: 0
Study 16131620 — intervention group
Group type: EXPERIMENTAL
Intervention: No-choice condition essays
Number of subjects: 0
Study 14634543 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg transdermal estradiol
Number of subjects: 148
Study 14634543 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg transdermal estradiol
Number of subjects: 148
Study 10567197 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 degrees passive head-up tilt
Number of subjects: 0
Study 10567197 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 degrees passive head-up tilt
Number of subjects: 0
Study 10567197 — intervention group
Group type: EXPERIMENTAL
Intervention: 53 degrees passive head-up tilt
Number of subjects: 0
Study 10567197 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 degrees passive head-up tilt
Number of subjects: 0
Study 10567197 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 0
Study 8530994 — intervention group
Group type: EXPERIMENTAL
Intervention: Real low-level laser (LLL) treatment (4 x 6 J per treatment, total of 20 treatments)
Number of subjects: 13
Study 8530994 — intervention group
Group type: COMPARATOR
Intervention: Placebo low-level laser treatment
Number of subjects: 13
Study 8530994 — intervention group
Group type: EXPERIMENTAL
Intervention: Real low-level laser (LLL) treatment
Number of subjects: 13
Study 1824798 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose medroxyprogesterone acetate (HD MAP) 1,000 mg b.i.d. p.o.
Number of subjects: 40
Study 1824798 — intervention group
Group type: COMPARATOR
Intervention: Oophorectomy (OPX)
Number of subjects: 40
Study 1824798 — intervention group
Group type: COMPARATOR
Intervention: Oophorectomy (OPX) after progression from HD MAP
Number of subjects: 40
Study 1824798 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose medroxyprogesterone acetate (HD MAP)
Number of subjects: 40
Study 1824798 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose medroxyprogesterone acetate (HD MAP) and Oophorectomy (OPX)
Number of subjects: 40
Study 6343871 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy
Number of subjects: 3064
Study 4087291 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin 5 mg dose
Number of subjects: 0
Study 4087291 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger doses of riboflavin
Number of subjects: 0
Study 29335751 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS (2.0 mA)
Number of subjects: 20
Study 29335751 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20
Study 26526444 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathological Internet Use (PIU) assessed using the Young Diagnostic Questionnaire (YDQ)
Number of subjects: 1444
Study 26526444 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous PIU symptoms and emotional problems
Number of subjects: 1444
Study 24753478 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonivamide treatment (NT) - 0.15 mg nonivamide added to 75 g glucose in 300 mL water
Number of subjects: 24
Study 24753478 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (CT) - 75 g glucose in 300 mL water
Number of subjects: 24
Study 24753478 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonivamide treatment (NT)
Number of subjects: 24
Study 24753478 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (CT)
Number of subjects: 24
Study 23536015 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast cancer survivors treated with chemotherapy
Number of subjects: 19
Study 23536015 — intervention group
Group type: COMPARATOR
Intervention: Age-matched female controls
Number of subjects: 19
Study 19887889 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy
Number of subjects: 348
Study 19887889 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive-experiential group therapy
Number of subjects: 348
Study 19887889 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual control group
Number of subjects: 348
Study 19061748 — intervention group
Group type: EXPERIMENTAL
Intervention: Single walking trials
Number of subjects: 27
Study 19061748 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous walking trials
Number of subjects: 27
Study 19061748 — intervention group
Group type: EXPERIMENTAL
Intervention: Single walking trials (young women)
Number of subjects: 27
Study 19061748 — intervention group
Group type: EXPERIMENTAL
Intervention: Single walking trials (older women)
Number of subjects: 27
Study 19061748 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous walking trials (young women)
Number of subjects: 27
Study 19061748 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous walking trials (older women)
Number of subjects: 27
Study 16607076 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 20
Study 16607076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11447732 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH-agonist leuprorelin acetate depot (LAD) 3.75 mg subcutaneously per month
Number of subjects: 48
Study 11447732 — intervention group
Group type: COMPARATOR
Intervention: Gestagen lynestrenol (LYN) 5 mg orally twice per day
Number of subjects: 48
Study 9675561 — intervention group
Group type: EXPERIMENTAL
Intervention: FSH-HP
Number of subjects: 120
Study 9675561 — intervention group
Group type: COMPARATOR
Intervention: FSH-HP + hMG
Number of subjects: 120
Study 8033761 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (100 mg on Days 1 and 3, and 150 mg on Day 5)
Number of subjects: 38
Study 2557869 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthrinse containing soluble pyrophosphate and a copolymer of methoxyethylene and maleic acid
Number of subjects: 0
Study 2557869 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthrinse containing only soluble pyrophosphate
Number of subjects: 0
Study 2557869 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthrinse
Number of subjects: 0
Study 1111465 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy
Number of subjects: 22
Study 1111465 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy (intermittent melphalan and prednisone)
Number of subjects: 22
Study 30257665 — intervention group
Group type: EXPERIMENTAL
Intervention: eLearning MHFA course
Number of subjects: 608
Study 30257665 — intervention group
Group type: EXPERIMENTAL
Intervention: blended MHFA course
Number of subjects: 608
Study 30257665 — intervention group
Group type: COMPARATOR
Intervention: Red Cross eLearning Provide First Aid (PFA)
Number of subjects: 608
Study 27462608 — intervention group
Group type: EXPERIMENTAL
Intervention: BodyPump group training (A)
Number of subjects: 143
Study 27462608 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual follow‐up by a personal trainer (B)
Number of subjects: 143
Study 27462608 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsupervised exercise (C)
Number of subjects: 143
Study 27462608 — intervention group
Group type: COMPARATOR
Intervention: Control group (D)
Number of subjects: 143
Study 25046944 — intervention group
Group type: EXPERIMENTAL
Intervention: Yigan Fupi Decoction (YFD)
Number of subjects: 116
Study 25046944 — intervention group
Group type: COMPARATOR
Intervention: Pinaverium Bromide Tablet
Number of subjects: 116
Study 22833021 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-caliber colonoscope
Number of subjects: 330
Study 22833021 — intervention group
Group type: COMPARATOR
Intervention: Standard colonoscope
Number of subjects: 330
Study 19704158 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT + CPT
Number of subjects: 102
Study 19704158 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT + FST
Number of subjects: 102
Study 19704158 — intervention group
Group type: COMPARATOR
Intervention: CPT
Number of subjects: 102
Study 17891683 — intervention group
Group type: COMPARATOR
Intervention: 14C-xylose breath test
Number of subjects: 101
Study 17891683 — intervention group
Group type: COMPARATOR
Intervention: 13C-xylose breath test
Number of subjects: 101
Study 17891683 — intervention group
Group type: COMPARATOR
Intervention: Gas fraction index (30 min/210 min)
Number of subjects: 101
Study 17891683 — intervention group
Group type: EXPERIMENTAL
Intervention: Gas fraction index after gluten-free diet
Number of subjects: 101
Study 15661459 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam 80 mg continuous infusion
Number of subjects: 60
Study 15661459 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam 120 mg continuous infusion
Number of subjects: 60
Study 15661459 — intervention group
Group type: COMPARATOR
Intervention: Placebo continuous infusion
Number of subjects: 60
Study 12878920 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg daily) + Cognitive Behavioral Therapy (CBT)
Number of subjects: 118
Study 12878920 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg daily) + Supportive Therapy
Number of subjects: 118
Study 12878920 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Cognitive Behavioral Therapy (CBT)
Number of subjects: 118
Study 12878920 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Supportive Therapy
Number of subjects: 118
Study 12878920 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg daily)
Number of subjects: 118
Study 9988404 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline (0.5 mg orally every week)
Number of subjects: 30
Study 9988404 — intervention group
Group type: COMPARATOR
Intervention: Placebo (orally every week)
Number of subjects: 30
Study 9988404 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy women)
Number of subjects: 30
Study 7487796 — intervention group
Group type: EXPERIMENTAL
Intervention: 75-200 mg dosage range of tricyclic antidepressant
Number of subjects: 0
Study 7487796 — intervention group
Group type: COMPARATOR
Intervention: 75-425 mg dosage range of tricyclic antidepressant
Number of subjects: 0
Study 2323695 — intervention group
Group type: COMPARATOR
Intervention: Hand-held applanation tonometer (HAT)
Number of subjects: 99
Study 2323695 — intervention group
Group type: EXPERIMENTAL
Intervention: Mackay‐Marg tonometer
Number of subjects: 99
Study 2323695 — intervention group
Group type: EXPERIMENTAL
Intervention: NCT A
Number of subjects: 99
Study 2323695 — intervention group
Group type: EXPERIMENTAL
Intervention: NCT B
Number of subjects: 99
Study 388987 — intervention group
Group type: EXPERIMENTAL
Intervention: Vivalan (viloxazine hydrochloride)
Number of subjects: 28
Study 388987 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 28
Study 31714584 — intervention group
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide (ATO) plus all‐trans retinoic acid (ATRA)
Number of subjects: 0
Study 31714584 — intervention group
Group type: COMPARATOR
Intervention: ATRA plus chemotherapy (CT)
Number of subjects: 0
Study 29344773 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid intervention (combination of online sexual health program and supplemental class lessons)
Number of subjects: 0
Study 29344773 — intervention group
Group type: EXPERIMENTAL
Intervention: Online videos for training
Number of subjects: 0
Study 29344773 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid intervention
Number of subjects: 0
Study 26294364 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary condition (free-living sedentary time increased by an average of 32 min/day)
Number of subjects: 43
Study 26294364 — intervention group
Group type: COMPARATOR
Intervention: Control condition (usual activity)
Number of subjects: 43
Study 26294364 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary condition
Number of subjects: 43
Study 24131664 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural oxycodone (0.1 mg kg(‐1))
Number of subjects: 24
Study 24131664 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxycodone (0.1 mg kg(‐1))
Number of subjects: 24
Study 22735432 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (60% of energy from carbohydrate, 20% from fat, 20% from protein; high glycemic load)
Number of subjects: 21
Study 22735432 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycemic index diet (40% from carbohydrate, 40% from fat, and 20% from protein; moderate glycemic load)
Number of subjects: 21
Study 22735432 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low-carbohydrate diet (10% from carbohydrate, 60% from fat, and 30% from protein; low glycemic load)
Number of subjects: 21
Study 22735432 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 21
Study 22735432 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycemic index diet
Number of subjects: 21
Study 22735432 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low-carbohydrate diet
Number of subjects: 21
Study 22735432 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone levels and metabolic syndrome components
Number of subjects: 21
Study 20089960 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine 3.5 mg/kg
Number of subjects: 1326
Study 20089960 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine 5.25 mg/kg
Number of subjects: 1326
Study 20089960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1326
Study 16089141 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenqi fuzheng injection (SFI)
Number of subjects: 85
Study 16089141 — intervention group
Group type: COMPARATOR
Intervention: No Shenqi fuzheng injection (SFI)
Number of subjects: 85
Study 16089141 — intervention group
Group type: COMPARATOR
Intervention: Radical operation
Number of subjects: 85
Study 12074185 — intervention group
Group type: EXPERIMENTAL
Intervention: Kiwifruit (1 kiwifruit per 30 kg bodyweight)
Number of subjects: 38
Study 12074185 — intervention group
Group type: COMPARATOR
Intervention: Normal diet without kiwifruit
Number of subjects: 38
Study 10480824 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted shared care intervention including multidisciplinary consultation, training of general practitioners and carers, and health education
Number of subjects: 220
Study 10480824 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 220